BioTuesdays
Profound Medical Logo
Markets

Profound Medical to begin trading on NASDAQ

Profound Medical’s (TSX:PRN; OTCQX:PRFMD) common shares have been certified for listing on The Nasdaq Stock Market, with trading slated to begin on Oct. 29 under the stock symbol “PROF.” The company’s common...

October 28, 2019
ekso
Markets

HCW starts Ekso Bionics at buy; PT $1.20

H.C. Wainwright launched coverage of Ekso Bionics Holdings (NASDAQ:EKSO) with a “buy” rating and $1.20 price target. The stock closed at 59 cents on Oct. 25. Ekso Bionics develops and markets robotic exoskeletons for...

October 28, 2019
Stoke Therapeutics
Markets

HCW starts Stoke Therapeutics at buy; PT $30

H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is advancing an antisense...

October 25, 2019
Titan Pharmaceuticals Logo
Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019
Senseonics
Markets

Stifel starts Senseonics at buy; PT $2

Stifel initiated coverage of Senseonics Holdings (NYSE American:SENS) with a “buy” rating and $2 price target. The stock closed at 95 cents on Oct. 22. Senseonics is an emerging company with a long-duration, implantable...

October 23, 2019
Dynavax
Markets

HCW starts Dynavax Technologies at buy; PT $13

H.C. Wainwright initiated coverage of Dynavax Technologies (NASDAQ:DVAX) with a “buy” rating and $13 price target based on an outlook for the sales growth of the company’s marketed hepatitis B vaccine, Heplisav-B. The...

October 18, 2019
Dyadic
Markets

Dawson James starts Dyadic at buy; PT $14

Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...

October 16, 2019
IGM Biosciences
Markets

Stifel starts IGM Biosciences at buy; PT $32

Stifel launched coverage of IGM Biosciences (NASDAQ:IGMS) with a “buy” rating and $32 price target. The stock closed at $17.25 on Oct. 11. “We believe the company’s first/only-in-class, IgM-based antibody platform...

October 14, 2019
Exagen
Markets

WB starts Exagen at outperform

William Blair initiated coverage of Exagen (NASDAQ:XGN) with an “outperform” rating based on an outlook for business trends, potential upside to revenue estimates, and its relative valuation to comparable diagnostic...

October 11, 2019
Aravive Logo
Markets

HCW starts Aravive at buy; PT $18

H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9. The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to...

October 10, 2019
Markets

SVB Leerink starts Mereo BioPharma at OP; PT $8

SVB Leerink initiated coverage of Mereo BioPharma Group PLC (NASDAQ:MREO) with an “outperform” rating and price target of $8. The stock closed at $2.89 on Oct. 9. “We believe this rare disease-focused biopharma company...

October 10, 2019
Vericel Logo
Markets

HCW starts Vericel at buy; PT $19

H.C. Wainwright initiated coverage of Vericel (NASDAQ:VCELL) with a “buy” rating and $19 price target. The stock closed at $13.82 on Oct. 8. Vericel, a commercial wound care company, markets two innovative tissue...

October 9, 2019
Satsuma Pharmaceuticals
Markets

SVB Leerink starts Satsuma Pharma at OP; PT $20

SVB Leerink launched coverage of Satsuma Pharmaceuticals (NASDAQ:STSA) with an “outperform” rating and $20 price target. The stock closed at $10.70 on Oct. 7. STS101, Satsuma’s lead asset, is a dry-powder formulation of...

October 8, 2019
Sutra-Biopharma-Logo
Markets

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

October 7, 2019
Markets

SVB Leerink ups AMAG Pharma PT to $14 from $9

SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...

October 7, 2019
Fulcrum Therapeutics
Markets

HCW starts Fulcrum Therapeutics at buy; PT $21

H.C. Wainwright launched coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a “buy” rating and $21 price target. The stock closed at $6.59 on Oct. 2. Fulcrum’s lead program, losmapimod, a p38 alpha/beta MAP kinase...

October 3, 2019
PhaseBio Pharmaceuticals
Markets

HCW starts PhaseBio Pharma at buy; PT $18

H.C. Wainwright initiated coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a “buy” rating and $18 price target. The stock closed at $4.03 on Oct. 2. PhaseBio’s Phase 2 candidate, PB2452, which is licensed from...

October 3, 2019
Fate Therapeutics
Markets

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

September 30, 2019